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ABSTRACT
Chemoresistance represents a major challenge for treatment of acute 
lymphoblastic leukemia (ALL). Thus, new drugs to overcome chemoresistance in ALL 
are urgently needed. To this end, we established a cytarabine (araC)-resistant ALL cell 
line (NALM-6/R), which interestingly displayed cross-resistance towards doxorubicin 
(ADM). Here we report that low dose of triptolide (TPL), a natural product used 
for treating inflammatory diseases such as arthritis, could reverse araC and ADM 
resistance and in NALM-6/R cells as well as primary cells from patients with relapsed 
or refractory (R/R) ALL, reflected by inhibition of cell proliferation and induction of 
apoptosis in vitro, and repression of tumor growth in vivo in a mouse xenograft model. 
Mechanistically, these events were associated with impaired mitochondrial membrane 
potential and increased reactive oxygen species (ROS) production. Co-treatment 
with TPL and araC or ADM upregulated pro-apoptotic caspase-9 protein, inhibited 
checkpoint kinase 1 (Chk1) and 2 (Chk2) phosphorylation, and induced fH2A.X (a 
DNA damage marker). Notably, the combination regimen of TPL and conventional 
chemotherapeutics also rapidly diminished tumor burden in a patient with R/R ALL. 
Together, these findings provide preclinical evidence for repurposing use of TPL in 
combination with chemotherapeutic agents to treat R/R ALL as an alternative salvage 
regimen.
INTRODUCTION
Although the remission rate has achieved > 80% in 
patients with newly-diagnosed adult acute lymphoblastic 
leukemia (ALL) with standard induction regimens, a 
majority of the responding patients eventually become 
refractory to initial therapy [1, 2]. 30-60% of these patients 
experience a relapse, despite aggressive chemotherapy 
regimens for consolidation and maintenance, even after 
allogeneic stem cell transplantation [3]. The outcome 
of patients with relapsed or refractory (R/R) adult ALL 
remains very poor. Whereas disease-free survival and 
complete remission of these patients are rare after salvage 
therapy, most of them die from the original disease [4]. 
Current chemotherapy for treating ALL involves complex 
regimens of multiple drugs that are carefully molded in 
order to eliminate minimal residual disease while spare 
normal hematopoiesis. However, de novo and acquired 
multidrug resistance of ALL cells represents the major 
barrier to the success of chemotherapy. Therefore, 
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discovery and development of new drugs to overcome 
multidrug resistance is urgently needed in treatment of 
R/R ALL patients.
Natural products, particularly those used for a 
long time in traditional Chinese medicine, have recently 
attracted a lot of attention in treatment of cancer, especially 
in reversing multidrug resistance [6]. Triptolide (TPL) is a 
diterpenoid epoxide, originally purified from the medicinal 
plant Tripterygium wilfordii Hook F (commonly known 
as lei gong teng) whose extracts have been used to treat 
a variety of diseases such as inflammation and arthritis 
in traditional Chinese medicine. TPL was structurally 
characterized in 1972 [5], and has been shown to have 
anti-inflammatory, immunosuppressive, as well as anti-
cancer activity. Recently, several groups including 
ours have demonstrated the potential benefit of TPL to 
overcome chemoresistance in different types of cancer 
[7-9], such as myeloid leukemia, pancreatic and ovarian 
cancer. However, the role and underlying mechanism of 
TPL in reversing chemoresistance in ALL have not been 
explored yet.
In the present study, we first established an araC-
resistant ALL cell line (NALM-6/R) by exposure of 
parental drug-naïve NALM-6 cells to stepwise increasing 
concentrations of cytarabine (araC), which also displayed 
cross-resistance towards doxorubicin (ADM). We then 
found that low dose TPL was able to re-sensitize NALM-
6/R cells to araC as well as doxorubicin(ADM) in vitro 
and in vivo, in association with production of reactive 
oxygen species (ROS) and inhibition of checkpoint 
kinase 1 (Chk1) and 2 (Chk2), resulting in DNA damage, 
mitochondrial injury, and apoptosis. The regimens 
combining TPL with araC or ADM were highly active 
against primary cells obtained from patients with R/R 
ALL. Of note, we also observed that treatment with TPL 
with conventional chemotherapeutics also rapidly reduced 
tumor burden in a patient with R/R ALL, without notable 
toxicity.
RESULTS
Establishment of a human ALL cell line acquired 
chemoresistance
We first established a drug-resistant cell line 
(designated NALM-6/R) by exposure of the human ALL 
NALM-6 cells to stepwise increasing concentrations of 
araC, after which the established NALM-6/R cell line 
was routinely maintained in the medium containing 5 
μM araC. The chemoresistant profile was evaluated by 
examine cytotoxicity of araC and other conventional 
anti-leukemia agents in vitro in parental drug-naïve 
NALM-6 and -resistant NALM-6/R cells. As shown 
in Table 1, the IC50 of araC against NALM-6/R cells 
(115.00 ± 23.12 μM) was 766 folds higher than that 
for parental NALM-6 cells (0.15 ± 0.07 μM; p< 0.01). 
Interestingly, NALM-6/R cells displayed marked 
cross-resistance towards ADM, with the IC50 of ADM 
in NALM-6/R cells (4.82 ± 0.97 μM) about 43 folds 
higher than that in parental NALM-6 cells (0.11 ± 0.03 
μM; p< 0.01). Of note, there was no cross-resistance to 
TPL observed in NALM-6/R cells (IC50 = 0.032 ± 0.04 
μM vs. 0.035 ± 0.03 μM for parental NALM-6 cells; p> 
0.05). These results demonstrate that NALM-6/R cells, 
a chemoresistant human ALL cell line established in 
vitro, are highly tolerated to cytotoxicity of conventional 
chemotherapeutic agents such as araC and ADM.
Low dose TPL enhances cytotoxicity of araC and 
ADM in NALM-6/R cells
The inhibitory effect of TPL, araC and ADM as 
single agent on growth of NALM-6/R cells was first 
examined. Neither araC within a concentration range 
of 0-5 μM nor ADM within a concentration range of 
0-0.5 μM exhibited significant proliferation inhibition in 
NALM-6/R cells after 48h exposure (Figure 1). However, 
in the presence of the IC20 concentration (i.e., 10 nM) of 
TPL, the IC50 of araC and ADM against NALM-6/R cells 
were reduced by 20 and 15 times, respectively (Table 2 
and Figure 1). These results suggest that low dose TPL 
might be capable to reverse chemoresistance against araC 
and ADM in ALL cells.
TPL potentiates araC- or ADM-induced 
apoptosis in both NALM-6/R cells and primary 
refractory or relapsed ALL cells
We then investigated whether the synergistic anti-
tumor effects between triptolide and araC or ADM stem 
from induction of apoptosis in chemoresistant ALL 
cells. To this end, NALM-6/R cells were exposed to the 
highest non-cytotoxic concentrations of araC (5 μM) or 
ADM (0.5 μM) in the presence or absence of low dose 
(IC20 concentration, 10 nM) TPL for 48 h. Notably, co-
administration of low dose TPL significantly increased 
apoptosis induced by araC or ADM from 10.21 ± 0.07% 
and 5.56 ± 0.04% to 52.40 ± 4.45% and 24.60 ± 3.23% 
(P < 0.01 for each case; Figure 2a and 2b), respectively. 
Consistently, combined treatment with 10 nM TPL and 
sub-toxic concentrations of araC or ADM significantly 
increased apoptosis in primary cells isolated from R/R 
ALL patients (n = 12; P < 0.01 for each case, compared 
araC or ADM as single agent; Figure 2c and Table 3). 
Notably, the regimens combining TPL with araC or ADM 
were more effective to induce apoptosis in primary R/R 
B-ALL cells from patients with white blood cell counts > 
100 x 109/L than those with < 100 x 109/L (P < 0.05; Table 
4). These findings suggest that TPL might re-sensitize 
chemoresistant ALL cells to araC or ADM.
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The combination of araC or ADM with 
TPL triggers reactive oxygen species (ROS) 
production and induces mitochondrial injury in 
ALL cells
Since mitochondria play a crucial role in regulation 
of apoptosis, apoptosis is often associated with loss of 
mitochondrial membrane potential (MMP) [10]. In this 
context, we then examine the effects of TPL and araC 
or ADM alone or in combination on MMP. As shown in 
Figure 3, whereas exposure to araC (5 μM) or ADM (0.5 
μM) resulted in a modest decrease in JC-1 aggregates, co-
administration of 10 nM TPL with either of these agents 
sharply reduced JC-1 aggregates (Figure 3a), reflecting 
loss of MMP (or mitochondrial depolarization), in NALM-
6/R cells (Figure 3b, P < 0.001 compared to each agent 
alone).
Moreover, considering the important role of ROS 
in depolarizing mitochondria and inducing apoptosis, 
we further measured the ROS levels in NALM-6/R cells 
after exposed to araC (5 μM) or ADM (0.5 μM) ± 10 nM 
TPL for 12h. Compared to treatment with each single 
agent, the combination of TPL with either araC or ADM 
significantly increased ROS generation by approximately 
9 and 5 folds in NALM-6/R cells, respectively. Notably, 
2h pre-treatment with the ROS scavenger NAC (30 mM) 
dramatically prevented ROS production induced by TPL 
plus araC or ADM (Figure 4), resulting in a marked 
reduction in apoptosis (from 52.40 ± 4.45% and 24.60 ± 
3.23% to 24.56 ± 3.17% and 14.15 ± 2.41%, respectively) 
in NALM-6/R cells (Figure 2b, P < 0.001). These findings 
indicate that TPL potentiates lethality of araC and ADM 
in chemoresistant ALL cells likely by inducing ROS 
generation and mitochondrial injury.
Combined treatment with TPL and araC 
or ADM disrupts DNA damage checkpoint, 
resulting in robust DNA damage in NALM-6/R 
cells
Both AraC and ADM, known as DNA cross-linking 
agents, act to induce DNA damage in cancer cells [11, 12], 
manifested by increased S139 phosphorylation of histone 
H2A.X (designated γH2A.X) at the sites of DNA double-
strand break [13]. As γH2A.X is commonly used as a 
marker for DNA damage, we next examined expression 
of γH2A.X to monitor the effects of TPL on DNA damage 
induced by araC or ADM. While TPL did not significantly 
affected the levels of γH2A.X, the combination of TPL 
with araC or ADM at the indicated doses resulted in a 
rightward shift of γH2A.X-FITC fluorescent peak in FACS 
histograms, indicating increased γH2A.X expression 
(Figure 5).
Further, Western blot was performed to assess 
the effects of TPL and araC or ADM alone or in 
combination on DNA damage checkpoint by monitoring 
phosphorylation of Chk1 (Ser345) and Chk2 (Thr68), 
which reflects cytoprotective activation of cell cycle 
checkpoints in response to DNA damage (e.g., induced by 
DNA-damaging agents, including araC and ADM) [14]. 
Notably, co-treatment with TPL markedly diminished 
phosphorylation of Chk1 and/or Chk2 triggered by araC 
and ADM, accompanied by a robust increase in γH2A.X 
expression (Figure 6), consistent with the results of flow 
cytometric analysis (Figure 5), and cleavage/activation of 
caspase 9. These findings suggest that disruption of DNA 
damage checkpoint might also contribute to reversal of 
chemoresistance by TPL in ALL cells.
The regimen combining TPL and araC is active 
in vivo in a xenograft mouse model generated 
from chemoresistant ALL cells
To validate the anti-leukemia activity of the 
regimen combining TPL and araC in vivo, we established 
a xenograft mouse model by intravenous injection with 
chemoresistant NALM-6/R cells into NSI (NOD-SCID-
IL2Rg-/-) mice. Of note, mice treated with TPL plus 
araC showed a substantial reduction of tumor burden, 
manifested by a marked decrease inCD45/CD19 double-
positive cells in bone marrow, compared to mice receiving 
each single agent (Figure 7a). Consistently, histopathology 
revealed a remarkable reduction of leukemia cell 
infiltration in bone marrow of mice receiving treatment 
with TPL plus araC (Figure 7b). Further, average spleen 
weight of mice treated with TPL plus araC (0.17 ± 0.26 g) 
Table 1: Cytotoxicity of TPL, araC ADM against drug-naïve NALM-6 cells and their chemoresistant NALM-6/R 
counterparts
Agents
IC50 (μM) Fold
increase P valueNALM-6 NALM-6/R
TPL 0.035 ± 0.003 0.032 ± 0.004 0.91 > 0.05
araC 0.15 ± 0.07 115.00 ± 23.12 766.67 < 0.01
ADM 0.11 ± 0.03 4.82 ± 0.97 43.82 < 0.01
Note: Cytotoxicity was assessed using the CCK-8 assay.
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were significantly lower than those of mice in the control 
group (0.31 ± 0.23 g), as well as each single agent group 
(0.28 ± 0.01g for TPL alone and 0.33 ± 0.56 g for araC 
alone; P <0.0001 for each case; Figure 7c). Last, Kaplan-
Meier analysis showed that the combination of TPL with 
araC significantly prolonged animal survival, compared to 
TPL or araC alone (P < 0.01, Figure 7d).
The combined therapy with TPL and 
chemotherapeutics rapidly reduces tumor 
burden in a patient with refractory B-ALL
Finally, we report the first use of TPL in combination 
with conventional chemotherapeutic agents to treat one 
patient with refractory ALL (patient #2, Table 3), who had 
no other treatment available when enrolled into this study. 
This pilot study was conducted with an approval from the 
Departmental Review Board and the patent’s informed 
consent. Data was collected prospectively. The patient 
was a 65-year-old female diagnosed with pre B-ALL with 
complex chromosome abnormalities. Even though two 
courses of induction chemotherapy including VDCLP and 
hyper-CVAD/A regimens were administrated, the response 
assessments unfortunately indicated a minor remission. At 
enrollment, the patient suffered from severe bone pain and 
fatigue; the complete blood count (CBC) revealed WBC 
count of 145×109/L; a high percentage of blasts (60 and 
86%, respectively) were detected on the smears of both 
peripheral blood (PB) and bone marrow (BM) aspirate; 
other laboratory tests included a basic metabolic panel, 
liver and coagulopathy panels, and renal function, which 
were all unremarkable. Considering the refractory status 
of the disease together with the results of the clinical 
tests, TPL in combination with the FA (fludarabine and 
cytarabine) regimen was then administered as salvage 
chemotherapy. The dose level of TPL was 100 μg/m2 
administered in 3 divided doses daily for 7 days, which 
was routinely used in clinic for treatment of rheumatoid 
arthritis [15]. TPL-related hematological or extra-
hematological toxicities, including the most serious side 
effects of TPL such as renal toxicity, were not observed 
during the course of treatment. Surprisingly, the patient 
experienced marked hematological improvement with 
an 80% reduction of peripheral blood blasts two weeks 
after treatment, and complete resolution of bone pain 
and fatigue. However, the prolonged response to TPL-
associated treatment remains to be defined.
DISCUSSION
Development of salvage regimens for adult patients 
with ALL has focused on the incorporation of alternative 
agents with their known roles in this disease. Most of the 
recently developed regimens involve the use of high-doses 
Figure 1: TPL re-sensitizes chemoresistant NALM-6/R cells to araC and ADM. NALM-6/R cells were exposed to the indicated 
concentrations of araC or ADM ± TPL (IC20: 10 nM) for 48 h, after which cell viabilities were determined by a CCK-8 assay. Values indicate 
mean ± SD for three independent experiments.
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of araC in combination with various other agents [16-
19]. However, efficacy of these regimens is significantly 
hampered by acquired drug-resistance to araC. Therefore, 
reversal of araC resistance might improve the clinical 
outcomes of ALL. To this end, we established an araC-
resistant ALL cell line (NALM-6/R), which unexpectedly 
was also cross-resistant to ADM. Of note, low dose TPL 
(10 nM) was able to increase the sensitivity of NALM-6/R 
cells to araC and ADM by 20 and 15 times, respectively. 
Further, low dose TPL also significantly increased 
apoptosis induced by araC and ADM in NALM-6/R cells. 
We further established a xenograft mouse model using 
these araC-resistant NALM-6/R cells, in which low dose 
TPL plus araC was also highly active in vivo, reflected by 
marked reduction of tumor burden and prolonged animal 
survival.
Importantly, low dose TPL also dramatically 
enhanced lethality of araC or ADM in primary leukemia 
blasts isolated from patients with R/RALL despite the 
cytogenetic subtypes. It is well established that disease 
burden at time of relapse is one of the most important 
prognostic factors of R/R ALL [4]. Interestingly, 
combined treatment with TPL and araC or ADM induced 
higher percentage of apoptosis in blasts of patients with 
WBC count > 100×109/L, than those with < 100×109/L, 
suggesting that this combination regimen might overcome 
the unfavorable effects of high tumor burden. However, 
further studies including more cases are needed to confirm 
this finding. Notably, after received the combination 
therapy of TPL with conventional chemotherapeutics, a 
patient with refractory ALL, who had no other treatment 
available, experienced hematological improvement 
with 80% reduction of peripheral blood blasts two 
weeks later. Taken together, these in vitro and in vivo 
findings argue strongly that low dose TPL might re-
sensitize chemoresistant ALL cells to conventional 
chemotherapeutic agents (e.g., araC and ADM), and 
thereby improve the outcome of patients with R/R ALL.
Chemotherapy represents a plethora of challenges 
to chromosomal DNA. Whereas DNA damage caused by 
various stimuli has been known to increase ROS levels 
[20], ROS can in turn induce a wide array of damages to 
DNA, therefore forming a positive feedback loop. DNA 
damage-induced ROS is important for determination 
of cell death versus survival [21]. The ability of cancer 
cells to distinguish ROS as a pro-survival from a pro-
apoptotic signal is dependent on the amount of ROS. 
While modest levels of ROS are required for cancer cells 
to survive, excessive ROS production is lethal to them. 
It has been reported that drug-resistant cells often have 
relatively higher basal levels of intrinsic oxidative stress, 
which might thus lower their threshold to lethal actions of 
ROS [22]. In the present study, we found that combined 
treatment with TPL and araC or ADM not only markedly 
increased ROS production, but also induced robust DNA 
damage in chemoresistantNALM-6/R cells. Moreover, 
pre-treatment with the antioxidant NAC attenuated ROS 
generation triggered by TPL plus araC or ADM, resulting 
in blockade of apoptosis, suggesting the functional role 
of elevated ROS levels in reversal of chemoresistance 
by TPL. Triptolide has previously been demonstrated to 
induce apoptosis by regulating members of the caspase 
family, in association with loss of MMP and activation 
of caspases in cancer cells [23, 24]. Notably, combined 
treatment with TPL and araC or ADM led to loss of 
MMP as well as cleavage/activation of caspase-9. Taken 
together, these findings argue that TPL in combination 
with araC or ADM triggers ROS production and induces 
DNA damage, cooperatively leading to activation of the 
mitochondria-mediated intrinsic apoptosis pathway.
Virtually all DNA-damaging agents currently used 
in cancer treatment induce apoptosis of cancer cells by 
inducing substantial DNA damage. It is well established 
that efficient and continual DNA repair is crucial for 
normal cells to survive, while it also represents an 
important mechanism for chemoresistance of tumor 
cells. Thus, defects or disruption of the DNA damage 
response (DDR), including DNA damage checkpoint 
and repair pathways, could sensitize cancer cells to 
genotoxic agents. For example, the Chk1 inhibitor 
7-Hydroxystaurosporine (UCN-01) has been shown to 
potentiate anti-tumor activity of the DNA-damaging 
agents such as gemcitabine and cytarabine [25]. DNA 
cross-linking agents activate checkpoint kinase 1 (Chk1) 
and 2 (Chk2), which are essential transducer of the DDR 
[14], which protect cells from lethal effects of genotoxic 
stress induced by these agents. In the present study, it 
was found that co-administration of TPL significantly 
Table 2: TPL-enhanced cytotoxicity of araC or ADM in NALM-6/R cells
Agents IC50 (μM) Fold decrease P value
AraC 45 ± 3.27 − < 0.01
AraC (+ TPL*) 2.25 ± 0.72 20.00
ADM 4.85 ± 0.95 − < 0.01
ADM (+ TPL*) 0.32 ± 0.081 15.16
Note: Cytotoxicity was assessed using the CCK-8 assay. * TPL = 10 nM (IC20 concentration).
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Figure 2: TPL increased apoptosis induced by araC or ADM in NALM-6/R cells, an event blocked by the antioxidant 
NAC, as well as in primary R/R ALL cells. a. NALM-6/R cells were exposed to araC (5 μM) or ADM (0.5 μM) ± TPL (IC20: 10 
nM) for 48 h, after which apoptotic ratios were determined by Annexin V/PI staining and flow cytometry. b. A column chart summarizes 
apoptotic ratios of NAML/R cells after drug treatments as described above for at least three independent experiments (mean ± SD). In 
addition, 30 mM NAC was added for 2 h to block ROS generation prior to combined treatment with TPL plus araC or ADM. c. Primary cells 
isolated from a patient with R/R ALL (patient #1 as shown in Table 3) were incubated with araC (5 μM) or ADM (0.5 μM) ± TPL (IC20: 10 
nM) for 48 h, after which apoptosis was analyzed Annexin V/PI staining and flow cytometry.
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Table 3: Effects of the regimens combining TPL with araC or ADM on primary blast cells of refractory or relapsed 
B-ALL patients (n = 12)
No Age/ sex
Disease 
status Cytogenetic
Prior 
therapy
Apoptotic cells (%)
Con TPL* araC ADM araC+TPL* ADM+TPL*
1 43/M Refractory t(9;22)
TKIs, 
VDLP; 
Hyper-
CVAD; 
Allo-SCT
32.71±3.13 34.32±3.65 37.28±5.70 36.53±2.65 58.46±8.78 51.47±10.16
2 65/F Refractory Complex
VDCLP; 
Hyper-
CVAD
38.70±4.28 54.84±3.25 52.76±4.89 62.31±5.17 81.76±3.42 89.27±4.33
3 19/F Relapse 2 Complex
VDLP; 
Hyper-
CVAD;FA
34.68±8.78 38.32±7.64 43.73±5.41 56.75±3.73 59.79±3.51 67.32±8.38
4 35/M Refractory t(9;11)
VDCLP; 
Hyper-
CVAD;FA
24.71±6.62 31.32±6.22 36.28±4.37 42.62±8.19 55.26±7.43 52.15±8.54
5 43/F Refractory t(5;14)
VDCLP; 
Hyper-
CVAD
27.52±7.14 32.25±2.67 38.78±3.69 36.62±10.3 54.52±4.71 48.25±3.16
6 62/M Relapse t(9;22) TKIs, VDLP 32.56±5.76 35.24±3.32 35.35±5.18 37.22±4.87 58.29±4.68 51.61±5.39
7 64/F Relapse 2 Hypodiploidy
VDCLP; 
CAM; MA; 
Hyper-
CVAD
36.28±6.29 39.11±2.67 42.68±3.72 45.51±5.62 60.37±4.31 54.49±7.48
8 17/F Refractory Complex
VDLP; 
Hyper-
CVAD; 
VDCLP
27.40±8.13 31.28±3.42 34.63±5.75 32.48±4.22 44.32±8.78 36.71±4.95
9 37/M Relapse t(4;11) VDCLP; CAM 26.52±3.68 32.61±7.73 37.31±6.15 30.22±5.34 42.86±6.38 34.47±9.59
10 26/F Refractory t(9;22)
TKIs, 
VDLP; 
Hyper-
CVAD
31.74±4.23 36.56±3.46 38.51±5.76 38.25±6.48 48.42±6.73 41.67±5.98
11 59/M Refractory Complex VDCLP; 
CAM;MA
36.86±4.37 36.17±2.36 41.51±3.45 40.69±5.78 46.87±6.22 44.54±5.34
12 28/F Relapse 2 Complex
VDCLP; 
CAM;MA; 
Hyper-
CVAD
24.73±3.74 31.28±4.38 34.21±3.67 37.27±5.38 39.18±6.23 44.02±7.43
Note: Percentage of apoptotic cells was determined by Annexin V/PI staining and flow cytometry. Values indicate mean ± SD for at least 
triplicate experiments. *TPL = 10 nM (IC20 concentration).
Relapse 2, patients with second relapse; Allo-SCT, allogeneic stem cell transplant; TKIs, tyrosine kinase inhibitors (imatinib or 
dasatinib; VD(C) LP: vincristine, daunorubicin, (cyclophosphamide), L-Asparaginase and prednisone; Hyper-CVAD: hyper-fractionated 
cyclophosphamide, vincristine, doxorubicin, and dexamethasone, alternating with high-dose methotrexate and cytarabine; FA: fludarabine 
and cytarabine; MA: mitoxantrone and cytarabine; CAM: cyclophosphamide, cytarabine, and 6-mercaptopurine.
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Figure 3: Combined treatment with TPL and araC or ADM results in mitochondrial injury in NALM-6/R cells. a. 
NALM-6/R cells were exposed to araC (5 μM) or ADM (0.5 μM) ± TPL (IC20: 10 nM) for 48 h, after which mitochondrial membrane 
potential (ΨΔm) was determined by monitoring JC-1 aggregates using flow cytometry. b. A column chart summarizes percentages of 
NAML/R cells with loss of ΨΔm (or mitochondrial membrane depolarization) after drug treatments as described above for at least three 
separate assays (mean ± SD).
Table 4: The relationship between WBC count and cytotoxicity of the regimens combining TPL with araC or ADM 
in primary refractory or relapsed B-ALL cells
WBC at biopsy  
(x109/L) P valueCon TPL* araC ADM araC+TPL* ADM+TPL*
Median 114
Range 23-146
>100 n = 7 33.74±4.83 39.37±8.25 42.87±6.46 45.85±11.52 61.36±10.12 59.67±15.12 < .05
<100 n = 5 30.93±4.23 35.01±4.23 38.07±3.27 37.15±4.04 42.52±3.61 40.08±5.72
Total n = 12 32.57±4.62 37.56±6.98 40.87±5.73 42.23±9.92 53.51±12.44 51.50±15.44 < .01
Note: Percentage of apoptotic cells was determined by Annexin V/PI staining and flow cytometry. Values indicate mean ± 
SD for the indicated number of patients. *TPL = 10 nM (IC20 concentration).
a
b
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Figure 4: Combined treatment with TPL and araC or ADM induce ROS production in NALM-6/R cells, an event 
prevented by NAC. NALM-6/R cells were exposed to araC (5 μM) or ADM (0.5 μM) ± TPL (IC20: 10 nM) for 12 h, as well as addition 
of 30 mM NAC for 2 h prior to combined treatments, after which ROS was measured using H2DCFDA dye and flow cytometry. Values 
indicate fold increases, compared to untreated control, for three separate experiments (mean ± SD).
Figure 5: Co-exposure to TPL and araC or ADM leads to increased expression of γH2A.X, a marker for DNA double-
strand break. NALM-6/R cells were exposed to araC (5 μM, left panel) or ADM (0.5 μM, right panel) ± TPL (IC20: 10 nM) for 48 h, 
after which cells were stained with anti-γH2A.X antibody for 1 h, followed by FITC-conjugated secondary antibody for 30 min, and then 
subjected to flow cytometric analysis.
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Figure 6: Co-treatment with TPL and araC or ADM disrupts DNA damage checkpoint and induces caspase 9 activation 
in NALM-6/R cells. NALM-6/R cells were exposed to araC (5 μM) or ADM (0.5 μM) ± TPL (IC20: 10 nM) for 48 h, after which Western 
blotting analysis was performed to monitor expression of γH2AX, p-Chk1, and pChk2, as well as cleavage/activation of caspase 9. The 
representative blots are shown for three independent experiments.
Figure 7: The regimen combining TPL with araC reduces tumor burden and prolongs animal survival in a mouse 
xenograft model of NALM-6/R cells. 5 × 105 NALM-6/R cells were subcutaneously injected via angular veins into sublethally 
irradiated adult NSI (NOD/SCID IL2rg-/-) mice. After 10 days, tumor-bearing mice were given intraperitoneally for 5 days with 100 μl 
ddH2O as control, 10 mg/kg araC, 0.5 mg/kg TPL, or TPL in combination with araC, respectively. On day 16 post tumor cell inoculation, 
flow cytometry was performed to monitor the number of human CD45/CD19 double-positive cells in bone marrow a.;
(Continued)
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Figure 7 (Continued): bone marrow sections were stained with H & E staining b.; spleen weight was measured c. Kaplan-Meier analysis 
was performed to assess animal survival d.
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inhibited phosphorylation/activation of Chk1 and Chk2 
induced by araC or ADM, accompanied by robust DNA 
damage and apoptosis. These results are consistent with 
a recent finding that TPL potentiates cisplatin-induced 
apoptosis by inhibiting DNA repair in lung cancer cells 
[26].
In summary, the present study demonstrates that 
low dose TPL could reverse chemoresistance of ALL 
cells to conventional DNA-damaging agents (e.g., araC- 
and ADM), at least in part through induction of ROS, 
disruption of the DDR, and increase of DNA damage. It 
also provides the preclinical and pilot clinical evidence 
suggesting that the potential clinical benefits of adding 
TPL into standard DNA-damaging agents-based 
chemotherapy regimens warrant attention in treatment of 
relapsed and refractory ALL patients.
MATERIALS AND METHODS
Chemicals and reagents
Triptolide (TPL, C20H24O6, MW: 360.40), 
cytarabine (araC, C9H13N3O5, MW: 243.22), doxorubicin 
(ADM, C27H29NO11, MW: 543.52), and N-acetyl-L-
cysteine (NAC) were purchased from Sigma-Aldrich 
(St. Louis, MO). TPL was dissolved in dimethyl 
sulfoxide (Sigma-Aldrich, Dorset, UK) as a 100 μM 
stock solution, and was freshly diluted in culture 
medium before use. Cytarabine, doxorubicin, were 
dissolved in phosphate-buffered saline (PBS) as a 100 
mM stock solution at -20°C. Light exposure was kept to 
a minimum for all drugs used.
Cell culture and patient samples
NALM-6 cells were obtained from the Institute 
of Hematology and Blood Diseases Hospital, Chinese 
Academy of Medical Sciences (Tianjin, China). The 
cells were routinely cultured in a RPMI 1640 medium 
(Invitrogen, USA), supplemented with 10% fetal bovine 
serum at 37°C in a humidified 5% CO2 incubator under 
standard conditions. AraC-resistant cells were established 
from the parental NALM-6 cells in our laboratory 
by continuous exposure to araC at low but gradually 
increasing concentrations, as described previously [27]. 
Finally, NALM-6/R cells were maintained in complete 
medium containing 5 μM of araC.
Relapsed or refractory acute lymphoblastic 
leukemia (R/R ALL) cases were defined according to the 
classification in the NCCN guidelines. Twelve cases of 
R/R ALL bone marrow or peripheral blood samples were 
obtained from the Nanfang Hospital, Southern Medical 
University. Major patient characteristics are summarized 
in Table 3. Mononuclear cells were isolated by standard 
Ficoll-Hypaque density centrifugation, and then 
cultured in RPMI-1640 supplemented with 10% fetal 
bovine serum. The acquisition of human bone marrow 
samples were approved by the local institutes and the 
experimental use of human specimens was carried out 
in accordance with the institutional guidelines and the 
Declaration of Helsinki. Acquisition of bone marrow 
samples was performed with the informed consent of 
patients.
In vitro cell proliferation assay
NALM-6/R cells were cultured in 96-well culture 
plates at a density of 5 × 104 cells/well in a medium 
containing different concentrations of araC, ADM, or 
combinations of these agents with fixed concentrations 
of TPL (IC20: 10 nM for 48 h) at 37°C in a humidified 5% 
CO2-95% air incubator. Cell inhibition was determined 
by a CCK8 assay, according to the manufacturer’s 
instructions (Beyotime Company, China). After 48 h, 
the cells were incubated in a 10 μl CCK-8 solution for 2 
h at 37°C. The absorbance of each well was quantified 
at 450 nm with an automated ELESA reader. IC50 
values were obtained using the logit method, and were 
determined from the results of at least 3 independent 
tests. The inhibition rate was calculated based on the 
following formula: Inhibition rate (%) = (1 - absorbance 
of experimental group/absorbance of control group) x 
100%.
Flow cytometric assays for cell apoptosis, 
mitochondrial membrane potential, reactive 
oxygen species and γH2A.X detection
After treated for 48 h, 2 x 105 NALM-6/R cells 
were subjected to apoptosis assay using an Annexin V 
Apoptosis Detection Kit-APC (eBioscience Company, 
USA), following the manufacturer’s instructions. For 
the mitochondrial membrane potential assessment, 
after different treatments for 48 h, 2 x 105 NALM-
6/R cells were analyzed using a JC-1 fluorescent 
probe kit (Beyotime Company, China), following the 
manufacturer’s instructions. To measure the intracellular 
reactive oxygen species (ROS) levels, about 2 x 105 
NALM/R cells subjected to different treatments were 
washed in PBS buffer twice, and then incubated in 1 ml 
of serum-free RPMI 1640 medium containing 10 μM of 
H2DCFDA for 30 min at 37°C. The cells were harvested, 
and then washed in serum-free RPMI 1640 medium buffer 
twice to remove the remaining H2DCFDA. The fluorescent 
intensity was measured by flow cytometry. For assessing 
the degree of DNA damage, 2 x 105 NALM-6/R cells 
were incubated for 15 min on ice in hybridization buffer 
(PBS containing 0.5% bovine serum albumin (BSA) and 
0.25% Triton X-100). After centrifugation, the cells were 
incubated with rabbit monoclonal anti-γH2A.X antibody 
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(Cell Signaling Technology, USA) for 1 h, then washed 
with PBS and incubated with an FITC-conjugated mouse 
anti-rabbit IgG antibody (BD Pharmingen) for 30 min in 
the dark at room temperature.
Western blot analysis
The cytoplasmic protein (50 μg/lane) from each 
sample was loaded onto a 10% SDS-PAGE gel, then 
transferred to a PVDF membrane (Millipore, Billerica, 
MA, USA) and blotted with the appropriate antibodies. 
Non-specific binding was avoided by blocking the 
PVDF membrane with 5% skimmed milk in TBS-T for 
1 h. The 5% skimmed milk in TBS-T was also used to 
dilute primary antibodies (phospho-γ-H2AX, rabbit 
mAb,1: 1000, CST; Phospho-Chk1 (Ser345) Rabbit mAb, 
detecting Chk1 phosphorylated at serine 345,1: 1000, 
CST; Phospho-Chk2 (Thr68) Rabbit mAb, detecting Chk2 
phosphorylated at Thr68,1: 1000, CST; caspase-9, mouse 
mAb, 1: 1000, CST) and HRP-conjugated secondary 
antibody (1: 10000; CST). The membranes were incubated 
in the primary antibodies overnight at 4°C and in the 
secondary antibody for 1 h at room temperature. The 
quantities of protein loaded were verified by staining the 
same membranes with anti-β-actin antibody (rabbit mAb 
1: 1000, CST). The signals were detected on X-ray films 
using an enhanced chemiluminescence western blotting 
detection kit (Amersham Pharmacia Biotech). β-Actin was 
included as a loading control.
Animal study
All animal experiments were performed in the 
Laboratory Animal Center of the Guangzhou Institute 
of Biomedicine and Health (GIBH), and the animal 
procedures were approved by the Animal Welfare 
Committee of GIBH. To generate a mouse model of 
araC-resistant ALL, we subcutaneously injected NALM-
6/R cells (5 × 105) into the angular veins of sublethally 
irradiated adult NSI (NOD/SCID IL2rg-/-) mice (20-30 g 
body weight; 2-3 months of age). Ten days later, 16 tumor-
bearing mice were divided into 4 groups and injected 
intraperitoneally with 100 μl with ddH2O, araC (10 mg/
kg, half of maximum tolerated dose in SCID mice [28]), 
TPL (0.5 mg/kg, 25% of lethal concentration [29]), or 
TPL in combination with araC for 5 days, respectively. 
We evaluated the responses to this treatment by measuring 
the overall survival times, the weights of the spleens and 
the percentages of human CD45/CD19 double-positive 
cells in the bone marrow, as assessed by flow cytometry. 
The tissue samples were fixed in formaldehyde and further 
embedded in paraffin.
Statistical analysis
Data was expressed as the mean ± standard 
deviation (S.D.) for at least three independent experiments 
and compared using the Student t-test. Multiple-group 
comparisons were performed using the One-way analysis 
of variance (ANOVA) followed by the Bonferroni posthoc 
test. Survival were estimated using the Kaplan-Meier 
analysis and compared using the log-rank test. P values 
< 0.05 were considered statistically significant. Statistical 
analyses were performed using SPSS 20.0 software (La 
Jolla, CA).
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